

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10725965
	Filing Date		2003-12-02
	First Named Inventor	Erik Buntinx	
	Art Unit	1627	
	Examiner Name	Umamaheswari Ramachandran	
Attorney Docket Number		29248/18	

U.S. PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	4797419		1989-01-10	Moos et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10725965
Filing Date	2003-12-02
First Named Inventor	Erik Buntinx
Art Unit	1627
Examiner Name	Umamaheswari Ramachandran
Attorney Docket Number	29248/18

1	BROWN E S, entitled "Extrapyramidal Side Effects with Low-Dose Risperidone," Can J Psychiatry (1997), Vol 42(3), pp. 325-326.	<input type="checkbox"/>
2	CALEY C F, entitled "Extrapyramidal Reactions from Concurrent SSRI and Atypical Antipsychotic Use," Can J Psychiatry (1998), Vol 43(3), pp. 307-308.	<input type="checkbox"/>
3	CITALOPRAM 10mg, 20mg and 40mg Tablets, 2 pages Actavis, Date of last revisions March 2007.	<input type="checkbox"/>
4	DIERICK, Michel et al., "A Double-Blind Comparison of Venlafaxine and Fluoxetine for Treatment of Major Depression in Outpatients," Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 1996, Vol. 20, pp. 57-71.	<input type="checkbox"/>
5	Remington's Pharmaceutical Sciences, "Structure Activity Relationship and Drug Design," 1980, pp. 420-425.	<input type="checkbox"/>
6	STELLA, Valentino J. et al., "Prodrug strategies to overcome poor water solubility," Advanced Drug Delivery Reviews 59 (2007) 677-694.	<input type="checkbox"/>
7	HEGERL, Ulrich et al., "The serotonin syndrome scale: first results on validity," Eur Arch Psychiatry Clin Neurosci (1998) 248: 96-103.	<input type="checkbox"/>
8	USPTO Notice of Allowance and Fee(s) Due dated 06/23/2010 in connection with U.S. Serial No. 10/752,423, filed 01/06/2001, Examiner Umamaheswari Ramachandran, Art Unit 1627.	<input type="checkbox"/>
9	USPTO Office Action dated 06/08/2010 in connection with U.S. Application Serial No. 10/803,793, filed 03/18/2004, Examiner Benjamin J. Packard, Art Unit 1612.	<input type="checkbox"/>
10	USPTO Office Action dated 06/23/2010 in connection with U.S. Application Serial No. 10/984,683, filed 11/09/2004, Examiner Anna Pagonakis, Art Unit 1628.	<input type="checkbox"/>
11	USPTO Office Action dated 03/18/2010 in connection with U.S. Application Serial No. 10/752,423, filed 01/06/2004, Examiner Umamaheswari Ramachandran, Art Unit 1627.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10725965
Filing Date	2003-12-02
First Named Inventor	Erik Buntinx
Art Unit	1627
Examiner Name	Umamaheswari Ramachandran
Attorney Docket Number	29248/18

12	BUNTINX E et al , Low dose pipamperone, enhancing antidepressant effect of citalopram, occupies 5HT _{2A} 50-60% leaving D ₂ nearly drug free. <u>European Neuropsychopharmacology</u> , Vol. 20, Supp. 3, August 2010, S386-S397, along with poster.	<input type="checkbox"/>
----	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.